Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Curigliano, Giuseppe [1 ,2 ]
Martin Jimenez, Miguel [3 ]
Shimizu, Toshio [4 ]
Keam, Bhumsuk [5 ]
Meric-Bernstam, Funda [6 ]
Rutten, Annemie [7 ]
Glaspy, John [8 ]
Parikh, Nehal S. [9 ]
Ising, Mary [9 ]
Hassounah, Nadia [9 ]
Wu, Jincheng [9 ]
Xu, Kun [10 ]
Choudhry, Somesh [10 ]
Garralda, Elena [11 ]
机构：
[1] Inst Europeo Oncol IRCCS, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[4] Natl Canc Ctr, Tokyo, Japan
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Sint Augustinus Hosp, Antwerp, Belgium
[8] Univ Calif Los Angeles, Los Angeles, CA USA
[9] Novartis Inst Biomed Res NIBR, Cambridge, MA USA
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Hosp Valle De Hebron, Barcelona, Spain
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT103
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.
    Calvo, Aitana
    Joensuu, Heikki
    Sebastian, Martin
    Naing, Aung
    Bang, Yung-Jue
    Martin, Miguel
    Roda, Desamparados
    Hodi, F. Stephen
    Veloso, Artur
    Mataraza, Jennifer
    Baneyx, Guillaume
    Guerreiro, Nelson
    Liao, Serena
    Rabault, Bertrand
    Fjaellskog, Marie-Louise
    Cervantes, Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
    Hong, David S.
    Schoffski, Patrick
    Calvo, Aitana
    Sarantopoulos, John
    De Olza, Maria Ochoa
    Carvajal, Richard D.
    Prawira, Amy
    Kyi, Chrisann
    Esaki, Taito
    Akerley, Wallace L.
    De Braud, Filippo G.
    Hui, Rina
    Zhang, Tian
    Soo, Ross A.
    Maur, Michela
    Weickhardt, Andrew James
    Chowdhury, Niladri Roy
    Sabatos-Peyton, Catherine
    Kwak, Eunice Lee
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies
    Curigliano, Giuseppe
    Gelderblom, Hans
    Mach, Nicolas
    Doi, Toshihiko
    Tai, Wai Meng David
    Forde, Patrick
    Sarantopoulos, John
    Bedard, Philippe L.
    Lin, Chia-Chi
    Hodi, Stephen
    Wilgenhof, Sofie
    Santoro, Armando
    Sabatos-Peyton, Catherine
    Longmire, Tyler
    Wan, Kitty
    Nikolopoulos, Panagiotis
    Manenti, Luigi
    Naing, Aung
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors
    Conlon, Kevin
    Leidner, Rom
    McNeel, Douglas
    Gupta, Sumati
    Wang-Gillam, Andrea
    Waldmann, Thomas A.
    Pavlakis, George
    Dostalek, Mirek
    Kurtulus, Sema
    Chowdhury, Niladri Roy
    O'Keeffe, Jessica
    Parikh, Nehal S.
    Thompson, John A.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies
    Curigliano, G.
    Jimenez, M. M.
    Shimizu, T.
    Keam, B.
    Meric-Bernstam, F.
    Rutten, A.
    Glaspy, J.
    Schuler, P. J.
    Parikh, N. S.
    Ising, M.
    Hassounah, N.
    Wu, J.
    Leyk, M.
    Chen, X.
    Burks, H.
    Chaudhury, A.
    Otero, J.
    Cabanas, E. Garralda
    ESMO OPEN, 2024, 9 (08)
  • [6] THE RECOMMENDED PHASE II DOSE SELECTION FOR SPARTALIZUMAB (PDR001), AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Sun, H.
    Sy, S.
    Xu, J.
    Hara, H.
    Cameron, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S41 - S41
  • [7] THE RECOMMENDED PHASE II DOSE SELECTION FOR SPARTALIZUMAB (PDR001), AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Sun, H.
    Sy, S.
    Xu, J.
    Hara, H.
    Cameron, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S73 - S73
  • [8] Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
    Uboha, Nataliya Volodymyrivna
    Milhem, Mohammed M.
    Kovacs, Christina
    Amin, Alpesh
    Magley, Andrea
    Das Purkayastha, D.
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies
    Ando, Yuichi
    Doi, Toshihiko
    Mitsuma, Ayako
    Mizutani, Takefumi
    Toyoda, Masanori
    Imamura, Yoshinori
    Kiyota, Naomi
    Naito, Yoichi
    Matsubara, Nobuaki
    Ishihara, Kae
    Tajima, Takeshi
    Tokushige, Kota
    Cameron, Scott
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.
    Bauer, Todd Michael
    Lin, Chia-Chi
    Greil, Richard
    Goebeler, Maria-Elisabeth
    Huetter-Kroenke, Marie Luise
    Garrido-Laguna, Ignacio
    Santoro, Armando
    Perotti, Antonella
    Spreafico, Anna
    Yau, Thomas
    Joerger, Markus
    Cremasco, Viviana
    Dostalek, Mirek
    Pelletier, Marc
    Barys, Louise
    Lu, Darlene
    Katsanou, Vicky
    Fabre, Claire
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345